Licence deal
Paris-based DNA engineering specialist Cellectis SA has granted GlaxoSmithKline plc a worldwide, non-exclusive sub-license to its gene targeting platform technology.
The technology is used to precisely substitute, delete or add genetic sequences at a chosen location in a genome, and is used in particular to generate mouse models of human disease.
The technology was invented at the Institut Pasteur in Paris. The licence gives GlaxoSmithKline the right to the technology for in vitro and in vivo modifications. Financial terms and conditions of the agreement were not disclosed.
Receive the Funding Newswire each Tuesday, our Policy Bulletin each Thursday, and news about bridging Europe’s east-west innovation gap twice a month in The Widening. 
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.
